The William Beaumont Hospital (WBH), located in the northwest Detroit suburb of Royal Oak, Michigan (997-beds) and in the growing suburb of Troy, Michigan (226-beds, twelve miles northeast of Royal Oak), seeks to become a highly productive contributor to the NCI?s Community Clinical Oncology Program. Against the background of Oakland and Macomb County?s population of nearly 2 million people and WBH?s cancer population of over 4,000 newly diagnosed each year, the proposed Beaumont CCOP (BCCOP) offers 100 multi-disciplinary investigators in 20 departments, including a very strong surgical component. The goals of the proposed BCCOP are to increase accrual of patients to treatment trials, to carefully follow patients and participants currently on study, and to continue to build cancer control capabilities.
The specific aims of the program are to reduce cancer incidence, morbidity, and mortality by accelerating the transfer of newly developed cancer prevention, early detection, treatment, patient management, rehabilitation, and continuing care technology to widespread community application, including a Minority Outreach Initiative. The methods include centralized research support through the Cancer Clinical Trials Office (CCTO), an experienced Institutional Review Board (IRB), credentialed pharmacy staff, as well as ongoing multidisciplinary site teams, a Protocol Review Committee (PRC), and a Steering Committee to guide the Beaumont CCOP. The Beaumont CCOP lives our motto: """"""""Today?s clinical trial for tomorrow?s standard of care.""""""""
|Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440|
|Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8|
|Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64|
|Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7|
|Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9|
|Kernstine, Kemp H; Moon, James; Kraut, Michael J et al. (2014) Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg 98:402-10|
|Philip, Philip A; Goldman, Bryan; Ramanathan, Ramesh K et al. (2014) Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO Cancer 120:2980-5|
|Hussain, Maha; Tangen, Catherine M; Berry, Donna L et al. (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368:1314-25|
|Zirpoli, Gary R; Brennan, Patrick M; Hong, Chi-Chen et al. (2013) Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res Treat 137:903-13|
|Mehta, Rita S; Barlow, William E; Albain, Kathy S et al. (2012) Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 367:435-44|
Showing the most recent 10 out of 22 publications